Literature DB >> 20689441

Cardiopulmonary exercise testing: a review of methods and applications in surgical patients.

Zoe A Ridgway1, Simon J Howell.   

Abstract

Cardiopulmonary exercise (CPX) testing has a number of medical applications, including the assessment of heart failure and the investigation of unexplained breathlessness. Over the past decade, it has become an important preoperative assessment tool to evaluate functional capacity and predict outcomes in patients undergoing both cardiac and noncardiac surgery. A CPX test is an incremental exercise test during which respiratory variables, including oxygen uptake and carbon dioxide excretion are measured and the ECG is monitored. Among the variables reported from a CPX test are oxygen uptake at anaerobic threshold and peak oxygen uptake. A limited functional capacity as indicated by a low anaerobic threshold or VO(2peak) has been shown to be associated with an increased incidence of perioperative complications in a number of surgical settings. Other reported variables, including the ventilatory equivalents for oxygen (VE/VO(2)) and carbon dioxide (VE/VCO(2)) and the millilitre of oxygen delivered per heartbeat or oxygen pulse [VO(2)/heart rate (HR)] may give indications as to the reasons for exercise limitation. ECG evidence of myocardial ischaemia with increasing workload is also an important indicator of increased perioperative risk. As a noninvasive, low-risk, test of the integrated responses to increasing cardiovascular stress, anaesthesiologists involved in preoperative assessment should have an understanding of its current uses and test outcomes. This review presents the physiological basis for CPX testing, methodology, advantages over other preoperative tests of cardiovascular function and guidance on the interpretation of CPX results in the perioperative setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689441     DOI: 10.1097/EJA.0b013e32833c5b05

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  7 in total

Review 1.  Pathophysiology and epidemiology of abdominal aortic aneurysms.

Authors:  Ian M Nordon; Robert J Hinchliffe; Ian M Loftus; Matt M Thompson
Journal:  Nat Rev Cardiol       Date:  2010-11-16       Impact factor: 32.419

2.  The utility of preoperative six-minute-walk distance in lung transplantation.

Authors:  Anthony W Castleberry; Brian R Englum; Laurie D Snyder; Mathias Worni; Asishana A Osho; Brian C Gulack; Scott M Palmer; R Duane Davis; Matthew G Hartwig
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

Review 3.  Cardiac Rehabilitation in Patients with Heart Failure.

Authors:  Tieh-Cheng Fu; Shu-Chun Huang; Chih-Chin Hsu; Chao-Hung Wang; Jong-Shyan Wang
Journal:  Acta Cardiol Sin       Date:  2014-09       Impact factor: 2.672

4.  Reduction in cardiorespiratory fitness after lung resection is not related to the number of lung segments removed.

Authors:  Elisabeth Edvardsen; Sigmund A Anderssen; Fredrik Borchsenius; Ole Henning Skjønsberg
Journal:  BMJ Open Sport Exerc Med       Date:  2015-10-05

5.  Adherence to Pre-operative Exercise and the Response to Prehabilitation in Oesophageal Cancer Patients.

Authors:  Laura J Halliday; Emre Doganay; Venetia Wynter-Blyth; Hayley Osborn; John Buckley; Krishna Moorthy
Journal:  J Gastrointest Surg       Date:  2020-04-20       Impact factor: 3.452

6.  Machine Learning for the Prediction of Complications in Patients After Mitral Valve Surgery.

Authors:  Haiye Jiang; Leping Liu; Yongjun Wang; Hongwen Ji; Xianjun Ma; Jingyi Wu; Yuanshuai Huang; Xinhua Wang; Rong Gui; Qinyu Zhao; Bingyu Chen
Journal:  Front Cardiovasc Med       Date:  2021-12-16

Review 7.  The Role of Cardiopulmonary Exercise Testing as a Risk Assessment Tool in Patients Undergoing Oesophagectomy: A Systematic Review and Meta-analysis.

Authors:  Jonathan Sivakumar; Harry Sivakumar; Matthew Read; Rhona C F Sinclair; Chistopher P Snowden; Michael W Hii
Journal:  Ann Surg Oncol       Date:  2020-06-02       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.